vs
Side-by-side financial comparison of ACME UNITED CORP (ACU) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $52.3M, roughly 1.7× ACME UNITED CORP). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 13.8%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -2.9%).
Acme United Corporation is a supplier of cutting, measuring and safety products for the school, home, office, hardware and industrial markets. The company was organized as a partnership in 1867 and incorporated in 1873 under the laws of the State of Connecticut. It is publicly traded on the NYSE American with symbol ACU.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
ACU vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $52.3M | $86.8M |
| Net Profit | $985.0K | — |
| Gross Margin | 39.7% | 67.4% |
| Operating Margin | 3.3% | -84.7% |
| Net Margin | 1.9% | — |
| Revenue YoY | 13.8% | 17.7% |
| Net Profit YoY | -40.4% | — |
| EPS (diluted) | $0.24 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $52.3M | — | ||
| Q4 25 | $47.5M | $86.8M | ||
| Q3 25 | $49.1M | $67.5M | ||
| Q2 25 | $54.0M | $60.0M | ||
| Q1 25 | $46.0M | $49.3M | ||
| Q4 24 | $45.9M | $73.7M | ||
| Q3 24 | $48.2M | $58.6M | ||
| Q2 24 | $55.4M | $31.1M |
| Q1 26 | $985.0K | — | ||
| Q4 25 | $1.9M | — | ||
| Q3 25 | $1.9M | $-91.3M | ||
| Q2 25 | $4.8M | $-111.7M | ||
| Q1 25 | $1.7M | $-116.2M | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $2.2M | $-83.5M | ||
| Q2 24 | $4.5M | $-97.1M |
| Q1 26 | 39.7% | — | ||
| Q4 25 | 38.2% | 67.4% | ||
| Q3 25 | 39.1% | 43.0% | ||
| Q2 25 | 41.0% | 5.5% | ||
| Q1 25 | 39.0% | -0.8% | ||
| Q4 24 | 38.7% | 68.7% | ||
| Q3 24 | 38.5% | 46.2% | ||
| Q2 24 | 40.8% | -0.8% |
| Q1 26 | 3.3% | — | ||
| Q4 25 | 6.1% | -84.7% | ||
| Q3 25 | 6.1% | -140.7% | ||
| Q2 25 | 11.8% | -189.8% | ||
| Q1 25 | 5.3% | -245.8% | ||
| Q4 24 | 5.0% | -117.5% | ||
| Q3 24 | 6.1% | -152.1% | ||
| Q2 24 | 11.5% | -327.6% |
| Q1 26 | 1.9% | — | ||
| Q4 25 | 3.9% | — | ||
| Q3 25 | 3.9% | -135.3% | ||
| Q2 25 | 8.8% | -186.2% | ||
| Q1 25 | 3.6% | -235.5% | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 4.6% | -142.7% | ||
| Q2 24 | 8.0% | -312.2% |
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.46 | — | ||
| Q3 25 | $0.46 | — | ||
| Q2 25 | $1.16 | $-0.33 | ||
| Q1 25 | $0.41 | $-0.36 | ||
| Q4 24 | $0.43 | $-0.24 | ||
| Q3 24 | $0.54 | $-0.28 | ||
| Q2 24 | $1.09 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.2M | $297.0M |
| Total DebtLower is stronger | $33.0M | — |
| Stockholders' EquityBook value | $116.7M | $698.6M |
| Total Assets | $195.2M | $913.2M |
| Debt / EquityLower = less leverage | 0.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $4.2M | — | ||
| Q4 25 | $3.6M | $297.0M | ||
| Q3 25 | $5.1M | $300.8M | ||
| Q2 25 | $3.6M | $301.2M | ||
| Q1 25 | $3.4M | $359.7M | ||
| Q4 24 | $6.4M | $323.8M | ||
| Q3 24 | $5.7M | $397.5M | ||
| Q2 24 | $3.8M | $412.5M |
| Q1 26 | $33.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $116.7M | — | ||
| Q4 25 | $117.6M | $698.6M | ||
| Q3 25 | $115.8M | $702.3M | ||
| Q2 25 | $113.7M | $698.5M | ||
| Q1 25 | $108.3M | $767.9M | ||
| Q4 24 | $107.0M | $710.4M | ||
| Q3 24 | $106.3M | $773.5M | ||
| Q2 24 | $104.0M | $768.5M |
| Q1 26 | $195.2M | — | ||
| Q4 25 | $171.0M | $913.2M | ||
| Q3 25 | $173.0M | $904.9M | ||
| Q2 25 | $170.9M | $907.4M | ||
| Q1 25 | $163.0M | $966.7M | ||
| Q4 24 | $162.2M | $910.4M | ||
| Q3 24 | $165.5M | $991.1M | ||
| Q2 24 | $173.5M | $964.3M |
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $8.2M | $-52.6M | ||
| Q3 25 | $7.1M | $-78.7M | ||
| Q2 25 | $6.3M | $-67.4M | ||
| Q1 25 | $-3.3M | $-103.7M | ||
| Q4 24 | $6.4M | $-73.3M | ||
| Q3 24 | $8.9M | $-59.0M | ||
| Q2 24 | $6.9M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $7.3M | $-61.9M | ||
| Q3 25 | $301.0K | $-89.5M | ||
| Q2 25 | $4.7M | $-74.9M | ||
| Q1 25 | $-4.7M | $-109.9M | ||
| Q4 24 | $4.7M | $-77.5M | ||
| Q3 24 | $7.5M | $-61.3M | ||
| Q2 24 | $4.4M | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | -71.3% | ||
| Q3 25 | 0.6% | -132.7% | ||
| Q2 25 | 8.7% | -124.9% | ||
| Q1 25 | -10.2% | -222.8% | ||
| Q4 24 | 10.2% | -105.1% | ||
| Q3 24 | 15.6% | -104.6% | ||
| Q2 24 | 8.0% | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 10.7% | ||
| Q3 25 | 13.8% | 16.1% | ||
| Q2 25 | 3.0% | 12.4% | ||
| Q1 25 | 2.9% | 12.6% | ||
| Q4 24 | 3.7% | 5.7% | ||
| Q3 24 | 2.8% | 3.9% | ||
| Q2 24 | 4.5% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.34× | — | ||
| Q3 25 | 3.72× | — | ||
| Q2 25 | 1.33× | — | ||
| Q1 25 | -2.02× | — | ||
| Q4 24 | 3.73× | — | ||
| Q3 24 | 3.99× | — | ||
| Q2 24 | 1.55× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACU
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
